Hospital
South Shore Hospital INC.
South Shore Hospital INC. was paid $95.13M by Medicaid between Jan 2018 and Dec 2024, across 363 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoSOUTH SHORE HOSPITAL INC.
SOUTH WEYMOUTH, MA 02190
SOUTH WEYMOUTH, MA 02190
33aNPI1134227606assigned 09/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$95.13M
24GClaims2,147,798
24DCodes billed363
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#16 of 66
Median peer was paid$29.11M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 245,909 | $10.87M | |
| 2019 | 247,856 | $9.76M | |
| 2020 | 224,324 | $8.26M | |
| 2021 | 316,893 | $12.67M | |
| 2022 | 366,034 | $16.53M | |
| 2023 | 413,493 | $18.93M | |
| 2024incomplete | 333,289 | $18.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 87,851 | 81,719 | $14.27M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 36,020 | 30,711 | $13.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.6% | 53,528 | 49,830 | $8.21M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.0% | 34,351 | 31,767 | $5.66M |
| S9485 | Crisis intervention mental health services, per diem | 3.1% | 6,578 | 3,448 | $2.91M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 15,227 | 14,644 | $2.37M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 19,073 | 17,754 | $2.34M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 17,193 | 16,281 | $2.11M |
| G0378 | Hospital observation service, per hour | 2.2% | 31,983 | 15,209 | $2.05M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.0% | 10,682 | 5,238 | $1.93M |
| 59025 | Fetal non-stress test | 1.9% | 7,555 | 4,771 | $1.84M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 1.9% | 11,177 | 9,724 | $1.82M |
351 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.8% | 12,583 | $1.72M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 27,539 | $1.70M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 16,277 | $1.69M |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 1.7% | 21,528 | $1.63M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 31,941 | $1.23M |
| A0425 | Ground mileage, per statute mile | 1.3% | 41,144 | $1.20M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 11,933 | $1.10M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 26,619 | $1.07M |
| A0427 | Emergency ambulance ride, advanced life support | 1.1% | 6,044 | $1.02M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 11,667 | $1.00M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14,174 | $831K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,943 | $793K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 23,641 | $730K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,325 | $657K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 510 | $602K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,828 | $602K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 851 | $601K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,050 | $600K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,226 | $589K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,876 | $583K |
| 93971 | <1% | 3,740 | $556K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 118,555 | $554K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,063 | $512K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,417 | $496K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,588 | $430K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,601 | $423K |
| 80053 | Comprehensive metabolic panel | <1% | 95,495 | $376K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 5,781 | $374K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 983 | $365K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,943 | $359K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,840 | $334K |
| 87632 | <1% | 1,945 | $326K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 31,062 | $303K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,116 | $295K |
| 97161 | <1% | 4,950 | $291K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 14,860 | $286K |
| 76642 | <1% | 2,630 | $272K | |
| 84484 | <1% | 39,102 | $271K | |
| ATP14 | <1% | 29,135 | $265K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,550 | $250K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,760 | $243K |
| 76830 | Ultrasound, transvaginal | <1% | 3,201 | $242K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,455 | $241K |
| 62323 | <1% | 915 | $225K | |
| 81513 | <1% | 2,200 | $221K | |
| 12001 | <1% | 1,036 | $199K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,245 | $194K |
| 97597 | <1% | 2,503 | $186K | |
| 84702 | <1% | 16,481 | $182K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,935 | $179K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,695 | $178K |
| J3490 | Unclassified drugs | <1% | 8,508 | $176K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 785 | $175K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,588 | $174K |
| 93017 | <1% | 2,403 | $169K | |
| 76813 | <1% | 1,019 | $168K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 825 | $152K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 970 | $144K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,590 | $139K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 89 | $127K |
| 76775 | <1% | 1,411 | $125K | |
| 83690 | <1% | 27,061 | $121K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,245 | $119K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 602 | $113K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,482 | $108K |
| 12011 | <1% | 473 | $105K | |
| 81025 | <1% | 17,878 | $96K | |
| 93970 | <1% | 642 | $95K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 38,370 | $92K |
| 97750 | <1% | 1,992 | $85K | |
| 97113 | <1% | 1,667 | $80K | |
| 99201 | <1% | 817 | $78K | |
| 97162 | <1% | 2,122 | $76K | |
| 83735 | <1% | 20,576 | $76K | |
| 90715 | <1% | 3,604 | $76K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,761 | $73K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28,072 | $71K |
| 73630 | <1% | 6,078 | $71K | |
| 86850 | <1% | 11,846 | $70K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,145 | $69K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,198 | $69K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,116 | $69K |
| 80050 | General health panel | <1% | 6,097 | $66K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 53,102 | $63K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,086 | $62K |
| 86141 | <1% | 7,663 | $61K | |
| 87634 | <1% | 1,008 | $61K | |
| 87481 | <1% | 2,223 | $60K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 6,750 | $60K |
| 87040 | <1% | 7,675 | $60K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 363 | $59K |
| 83880 | <1% | 3,465 | $57K | |
| 80061 | Lipid panel | <1% | 14,047 | $53K |
| 83605 | <1% | 8,178 | $52K | |
| A0434 | Specialty care transport (sct) | <1% | 95 | $51K |
| 86618 | <1% | 3,356 | $51K | |
| 85610 | <1% | 29,803 | $50K | |
| 73610 | <1% | 4,677 | $50K | |
| 85379 | <1% | 7,533 | $49K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,539 | $48K |
| 85027 | <1% | 12,863 | $47K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,907 | $47K |
| 81001 | <1% | 23,796 | $47K | |
| ATP08 | <1% | 7,877 | $45K | |
| 73130 | <1% | 3,673 | $44K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,411 | $44K |
| 82803 | <1% | 3,146 | $42K | |
| 77065 | Tomosynthesis, mammo | <1% | 800 | $41K |
| 74018 | <1% | 1,641 | $40K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 52,648 | $38K |
| 81003 | <1% | 24,163 | $38K | |
| 73110 | <1% | 3,032 | $38K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,416 | $37K |
| 97165 | <1% | 521 | $37K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,130 | $36K |
| 87070 | <1% | 6,460 | $35K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 855 | $35K |
| 73030 | <1% | 3,235 | $35K | |
| 76801 | <1% | 1,466 | $34K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,921 | $34K |
| 86803 | <1% | 3,311 | $34K | |
| 82728 | <1% | 4,018 | $33K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 27,978 | $33K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 17 | $32K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 38 | $32K |
| 86900 | <1% | 11,923 | $31K | |
| 82607 | <1% | 3,470 | $29K | |
| 87186 | <1% | 5,828 | $29K | |
| 72110 | <1% | 1,613 | $29K | |
| 87081 | <1% | 5,403 | $28K | |
| 73564 | <1% | 3,769 | $28K | |
| 87077 | <1% | 6,238 | $28K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 24,276 | $27K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 176 | $27K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,609 | $27K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 946 | $27K |
| 77062 | <1% | 247 | $26K | |
| 70496 | <1% | 275 | $26K | |
| ATP15 | <1% | 3,162 | $25K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,107 | $25K |
| 86780 | <1% | 2,283 | $25K | |
| 93308 | <1% | 144 | $25K | |
| 76870 | <1% | 307 | $24K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,621 | $23K |
| 86901 | <1% | 11,876 | $23K | |
| 76536 | <1% | 231 | $22K | |
| 82330 | <1% | 3,094 | $22K | |
| 93798 | <1% | 279 | $22K | |
| 82375 | <1% | 3,120 | $21K | |
| 12002 | <1% | 112 | $20K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,324 | $20K |
| 77061 | <1% | 186 | $19K | |
| 71250 | <1% | 602 | $19K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,309 | $18K |
| 87205 | <1% | 6,454 | $17K | |
| A0998 | Ambulance response and treatment, no transport | <1% | 146 | $17K |
| 74019 | <1% | 2,527 | $17K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,106 | $17K |
| 71271 | <1% | 299 | $16K | |
| 73140 | <1% | 1,168 | $16K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 82 | $16K |
| 73502 | <1% | 1,613 | $16K | |
| 97760 | <1% | 188 | $16K | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 1,036 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,262 | $15K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,198 | $15K |
| 10060 | <1% | 79 | $15K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13,492 | $15K |
| 83550 | <1% | 2,823 | $14K | |
| 73080 | <1% | 1,277 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,705 | $14K |
| 84439 | <1% | 2,751 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,246 | $14K |
| 70491 | <1% | 113 | $14K | |
| 70486 | <1% | 672 | $14K | |
| 77066 | Tomosynthesis, mammo | <1% | 483 | $14K |
| 72141 | <1% | 39 | $13K | |
| 83050 | <1% | 3,132 | $13K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,313 | $13K |
| 83540 | <1% | 3,358 | $13K | |
| 96376 | <1% | 12,241 | $13K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,984 | $12K |
| 70498 | <1% | 394 | $12K | |
| 99220 | <1% | 592 | $12K | |
| 87340 | <1% | 1,437 | $12K | |
| 94060 | <1% | 98 | $11K | |
| 82962 | <1% | 24,898 | $11K | |
| 85007 | <1% | 5,069 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,641 | $10K |
| 85652 | <1% | 5,736 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 872 | $9K |
| 86706 | <1% | 1,129 | $9K | |
| 82150 | <1% | 2,330 | $9K | |
| 84100 | <1% | 6,738 | $8K | |
| 82570 | <1% | 2,675 | $8K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,353 | $8K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 4,863 | $8K |
| 82746 | <1% | 916 | $8K | |
| 84302 | <1% | 2,984 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 72 | $7K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,082 | $7K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,560 | $7K |
| 73590 | <1% | 1,100 | $7K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 28 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 40 | $6K |
| 82550 | <1% | 3,689 | $6K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 8,557 | $6K |
| 82043 | <1% | 2,128 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 26 | $6K |
| 73090 | <1% | 706 | $6K | |
| 84145 | <1% | 1,255 | $5K | |
| 95806 | <1% | 26 | $5K | |
| 97116 | <1% | 244 | $5K | |
| 88304 | <1% | 1,515 | $5K | |
| 11045 | <1% | 47 | $5K | |
| 85730 | <1% | 1,337 | $5K | |
| 90686 | <1% | 689 | $5K | |
| 99218 | <1% | 63 | $5K | |
| 84550 | <1% | 1,401 | $5K | |
| 80076 | <1% | 2,924 | $5K | |
| 94726 | <1% | 90 | $4K | |
| 86762 | <1% | 354 | $4K | |
| 76882 | <1% | 51 | $4K | |
| 94729 | <1% | 87 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,495 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,415 | $4K |
| 74183 | <1% | 12 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 90 | $3K |
| ATP03 | <1% | 3,353 | $3K | |
| 81015 | <1% | 1,516 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,973 | $3K |
| 74174 | <1% | 80 | $3K | |
| 88342 | <1% | 96 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,412 | $3K |
| 76820 | <1% | 42 | $3K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,387 | $2K |
| 80164 | <1% | 740 | $2K | |
| 86308 | <1% | 566 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,875 | $2K |
| 72050 | <1% | 26 | $2K | |
| 87147 | <1% | 516 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,777 | $2K |
| 86787 | <1% | 171 | $2K | |
| ATP09 | <1% | 280 | $2K | |
| 83001 | <1% | 119 | $2K | |
| 80074 | <1% | 46 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 102 | $2K |
| J1836 | Injection, metronidazole, 10 mg | <1% | 339 | $2K |
| 0031A | <1% | 152 | $2K | |
| 88112 | <1% | 57 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,401 | $2K |
| 84132 | <1% | 2,036 | $2K | |
| 96367 | <1% | 457 | $2K | |
| 84156 | <1% | 485 | $1K | |
| 85014 | <1% | 710 | $1K | |
| 87506 | <1% | 12 | $1K | |
| 77080 | <1% | 38 | $1K | |
| 0001A | <1% | 32 | $1K | |
| 0002A | <1% | 30 | $1K | |
| 86617 | <1% | 72 | $1K | |
| 82947 | <1% | 1,356 | $1K | |
| 87420 | <1% | 111 | $1K | |
| 83970 | <1% | 158 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,109 | $1K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,086 | $997.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 140 | $946.38 |
| 29581 | <1% | 25 | $937.32 | |
| 82310 | <1% | 303 | $935.65 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,260 | $926.51 |
| 73552 | <1% | 48 | $884.40 | |
| 76376 | <1% | 31 | $869.89 | |
| 87808 | <1% | 99 | $836.99 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $828.90 |
| 87207 | <1% | 140 | $603.22 | |
| 84403 | <1% | 25 | $579.27 | |
| G0008 | Administration of influenza virus vaccine | <1% | 680 | $530.99 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 20 | $481.97 |
| 82010 | <1% | 111 | $480.36 | |
| A4649 | Surgical supply; miscellaneous | <1% | 562 | $472.68 |
| 85018 | <1% | 241 | $472.18 | |
| 84146 | <1% | 26 | $424.88 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,488 | $361.39 |
| 0011A | <1% | 41 | $358.90 | |
| 73562 | <1% | 31 | $324.75 | |
| 86431 | <1% | 53 | $245.35 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 118 | $232.34 |
| 82565 | <1% | 206 | $231.86 | |
| 72132 | <1% | 25 | $217.07 | |
| 76937 | <1% | 62 | $216.81 | |
| Q3014 | Telehealth originating site facility fee | <1% | 187 | $214.23 |
| 80178 | <1% | 98 | $195.70 | |
| 82140 | <1% | 14 | $167.05 | |
| 72072 | <1% | 13 | $155.54 | |
| ATP18 | <1% | 22 | $153.58 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 30 | $152.72 |
| ATP17 | <1% | 26 | $143.36 | |
| 82950 | <1% | 32 | $136.92 | |
| 87075 | <1% | 26 | $136.21 | |
| 72170 | <1% | 13 | $116.65 | |
| 73560 | <1% | 12 | $107.94 | |
| 83718 | <1% | 12 | $89.76 | |
| 73060 | <1% | 29 | $78.84 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 880 | $78.76 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,299 | $75.73 |
| 84450 | <1% | 37 | $71.36 | |
| 86708 | <1% | 14 | $67.80 | |
| 82465 | <1% | 12 | $64.44 | |
| 89051 | <1% | 13 | $59.28 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 40 | $59.13 |
| 82247 | <1% | 16 | $57.59 | |
| 80177 | <1% | 14 | $46.76 | |
| 99152 | <1% | 1,045 | $32.81 | |
| 90694 | <1% | 123 | $24.70 | |
| 84153 | <1% | 18 | $17.36 | |
| 83615 | <1% | 90 | $16.50 | |
| 84460 | <1% | 35 | $10.92 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 226 | $3.60 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 115 | $1.28 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 174 | $0.65 |
| 99153 | Mod sedat endo service >5yrs | 0% | 652 | $0.00 |
| 80320 | 0% | 302 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 484 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,573 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 188 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 12 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 112 | $0.00 |
| 80329 | 0% | 122 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 100 | $0.00 |
| 88300 | 0% | 17 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 33 | $0.00 |
| 0012A | 0% | 30 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 48 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 15 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | 0% | 12 | $0.00 |
| 80306 | 0% | 3,824 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 7,507 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 584 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 142 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 118 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 407 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 691 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 678 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 56 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 106 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 31 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 14 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| 99219 | 0% | 13 | $0.00 | |
| 72129 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOCO, STEVEN (SVP/CFO)